Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Fairview Medical Oncology Clinic
mi
from
Edina, MN
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Fairview Medical Oncology Clinic
mi
from
Edina, MN
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
St. Louis Cancer Care
mi
from
Chesterfield, MO
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
St. Louis Cancer Care
mi
from
Chesterfield, MO
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Research Medical Center
mi
from
Kansas City, MO
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
St. John's Clinic
mi
from
Springfield, MO
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
St. John's Clinic
mi
from
Springfield, MO
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Methodist Cancer Center
mi
from
Omaha, NE
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Methodist Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
St. Clare's Hospital Oncology and Hematology
mi
from
Denville, NJ
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
St. Clare's Hospital Oncology and Hematology
mi
from
Denville, NJ
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Southern Oncology Hematology
mi
from
Vineland, NJ
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Southern Oncology Hematology
mi
from
Vineland, NJ
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
New Mexico Oncology Hematology Consultants
mi
from
Albuquerque, NM
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
New Mexico Oncology Hematology Consultants
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Alamance Regional Medical Center
mi
from
Burlington, NC
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Alamance Regional Medical Center
mi
from
Burlington, NC
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Mid Ohio Oncology/Hematology, Inc., dba, The Mark H. Zangmeister Center
mi
from
Columbus, OH
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Mid Ohio Oncology/Hematology, Inc., dba, The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Hematology/Oncology Inc
mi
from
Elyria, OH
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Hematology/Oncology Inc
mi
from
Elyria, OH
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Hickman Cancer Center at Flower Hospital
mi
from
Sylvania, OH
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Hickman Cancer Center at Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Bux-Mont Oncology, Fox Chase Cancer Center
mi
from
Rockledge, PA
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Bux-Mont Oncology, Fox Chase Cancer Center
mi
from
Rockledge, PA
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Medical University of South Carolina
mi
from
Charleston, SC
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Lowcountry Hematology & Oncology, PA
mi
from
Mt. Pleasant, SC
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Lowcountry Hematology & Oncology, PA
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Coastal Cancer Center
mi
from
Myrtle Beach, SC
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Coastal Cancer Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
The Family Cancer Center
mi
from
Collierville, TN
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
The Family Cancer Center
mi
from
Collierville, TN
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Coastal Bend Cancer Center
mi
from
Corpus Christi, TX
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Coastal Bend Cancer Center
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
The Center for Cancer and Blood Disorders
mi
from
Ft. Worth, TX
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
The Center for Cancer and Blood Disorders
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Medical Oncology Methodist Hospital
mi
from
Houston, TX
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Medical Oncology Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
Virginia Cancer Institute
mi
from
Richmond, VA
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/1/2016
San Juan Hospital
mi
from
San Juan,
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/1/2016
San Juan Hospital
mi
from
San Juan,
Click here to add this to my saved trials
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Washington,
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Miami, FL
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Atlanta, GA
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
St. Louis, MO
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer
Status: Enrolling
Updated:  6/2/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer
Status: Enrolling
Updated: 6/2/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
Status: Enrolling
Updated:  6/2/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
Status: Enrolling
Updated: 6/2/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated:  6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated: 6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
Click here to add this to my saved trials
Educational Intervention for Reducing Work Disability in Breast Cancer Survivors
Reducing Work Disability in Breast Cancer Survivors
Status: Enrolling
Updated:  6/14/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Educational Intervention for Reducing Work Disability in Breast Cancer Survivors
Reducing Work Disability in Breast Cancer Survivors
Status: Enrolling
Updated: 6/14/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Patient Navigation in the Safety Net:CONNECTeDD
Patient Navigation in the Safety Net:CONNECTeDD
Status: Enrolling
Updated:  6/14/2016
Boston Med Ctr
mi
from
Boston, MA
Patient Navigation in the Safety Net:CONNECTeDD
Patient Navigation in the Safety Net:CONNECTeDD
Status: Enrolling
Updated: 6/14/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated:  6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated: 6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated:  6/16/2016
Tufts University Medical Center
mi
from
Boston, MA
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Status: Enrolling
Updated: 6/16/2016
Tufts University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated:  6/20/2016
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated: 6/20/2016
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated:  6/20/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated: 6/20/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated:  6/20/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated: 6/20/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated:  6/20/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Status: Enrolling
Updated: 6/20/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials